Metrics to compare | DYAI | Sector Sector - Average of metrics from a broad group of related Healthcare sector companies | Relationship RelationshipDYAIPeersSector | |
|---|---|---|---|---|
P/E Ratio | −4.0x | −1.2x | −0.4x | |
PEG Ratio | 0.50 | −0.28 | 0.00 | |
Price/Book | −72.0x | 2.3x | 2.6x | |
Price / LTM Sales | 7.7x | 6.0x | 3.0x | |
Upside (Analyst Target) | - | 148.4% | 57.3% | |
Fair Value Upside | Unlock | 7.5% | 8.9% | Unlock |
Dyadic International, Inc., together with its subsidiaries, a biotechnology platform company, develops, manufactures, and commercializes proteins and enzymes in the United States. The company offers Dapibus Protein Production Platform, a proprietary expression system designed to produce non-animal proteins and enzymes for non-pharmaceutical markets, including life sciences, food and nutrition, and bio-industrial sector; and C1 Protein Production Platform, a thermophilic fungal platform for large-scale production of proteins. It has a research and development agreement with VTT Technical Research Centre of Finland, Ltd; license agreement with Rubic One Health to develop various livestock vaccines; sub-license agreement with Phibro Animal Health/Abic Biological Laboratories to develop vaccines and treatments for livestock diseases; and collaboration with Scripps Research to evaluate monoclonal antibody and vaccine candidates targeting hantaviruses. Dyadic International, Inc. was founded in 1979 and is headquartered in Jupiter, Florida.